Half-year report · HY
4583.TEDINET S100YW7X
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥274m | 2026-01-01 → 2026-06-30 | Standalone | Net sales |
| Revenue | ¥593m | 2025-01-01 → 2025-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥252m | 2025-01-01 → 2025-06-30 | Standalone | Net sales |
| Operating income | −¥480m | 2026-01-01 → 2026-06-30 | Standalone | Operating income |
| Operating income | −¥537m | 2025-01-01 → 2025-06-30 | Standalone | Operating income |
| Ordinary income | −¥482m | 2026-01-01 → 2026-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥989m | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥539m | 2025-01-01 → 2025-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥482m | 2026-01-01 → 2026-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥539m | 2025-01-01 → 2025-06-30 | Standalone | Income before income taxes |
| Net income | −¥483m | 2026-01-01 → 2026-06-30 | Standalone | Profit loss |
| Net income | −¥983m | 2025-01-01 → 2025-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥540m | 2025-01-01 → 2025-06-30 | Standalone | Profit loss |
| Total assets | ¥1.9bn | at 2026-06-30 | Standalone | Assets |
| Total assets | ¥1.7bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2025-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥341m | at 2026-06-30 | Standalone | Liabilities |
| Total liabilities | ¥605m | at 2025-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.6bn | at 2026-06-30 | Standalone | Net assets |
| Net assets / equity | ¥1.1bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.5bn | at 2025-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.4bn | at 2026-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.4bn | at 2026-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2025-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2025-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31v | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥539m | 2026-01-01 → 2026-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥936m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥673m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥4m | 2026-01-01 → 2026-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥55m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥710m | 2026-01-01 → 2026-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥133m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥85m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-6.62 | 2026-01-01 → 2026-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-14.47 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.97 | 2025-01-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 81.9% | at 2026-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.9% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 78,940,200 | at 2026-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 68,453,800 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 68,053,800 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥269m |
| Drug Discovery And Developmentreportable segment | segment profit | 2026-01-01 → 2026-06-30 | −¥369m |
| Drug Discovery Supportreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥274m |
| Drug Discovery Supportreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥274m |
| Drug Discovery Supportreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥159m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2026-01-01 → 2026-06-30 | ¥274m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2026-01-01 → 2026-06-30 | ¥274m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2026-01-01 → 2026-06-30 | −¥210m |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥280m |
| Drug Discovery And Developmentreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥396m |
| Drug Discovery Supportreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥252m |
| Drug Discovery Supportreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥252m |
| Drug Discovery Supportreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-06-30 | ¥252m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-06-30 | ¥252m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-06-30 | −¥257m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 430
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoverySupportReportableSegmentsMember | 273659000 | JPY |
| Revenues from external customers | InterimDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 273659000 | JPY |
| Revenues from external customers | InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration_NonConsolidatedMember | 273659000 | JPY |
| Transactions with other segments | InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoverySupportReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | InterimDuration_NonConsolidatedMember | － | JPY |
| Net sales | InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | － | JPY |
| Net sales | InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoverySupportReportableSegmentsMember | 273659000 | JPY |
| Net sales | InterimDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | 273659000 | JPY |
| Net sales | InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | － | JPY |
| Net sales | InterimDuration_NonConsolidatedMember | 273659000 | JPY |
| Operating income | InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember | -368984000 | JPY |
| Operating income | InterimDuration_NonConsolidatedMember_jpcrp040300-ssr_E26096-000DrugDiscoverySupportReportableSegmentsMember | 158522000 | JPY |
| Operating income | InterimDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember | -210462000 | JPY |
| Operating income | InterimDuration_NonConsolidatedMember_ReconcilingItemsMember | -269254000 | JPY |
| Operating income | InterimDuration_NonConsolidatedMember | -479717000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-08-13 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第23期中（自 2026年１月１日 至 2026年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Company name in english cover page | FilingDateInstant | Chiome Bioscience Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 小池 正道 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区本町三丁目12番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03-6383-3561 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)管理本部長 田中 美旋律 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区本町三丁目12番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03-6383-3561 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)管理本部長 田中 美旋律 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E26096 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45830 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社カイオム・バイオサイエンス | |
| Filer name in english | FilingDateInstant | Chiome Bioscience Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | false | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2026-01-01 | |
| Current period end date | FilingDateInstant | 2026-06-30 | |
| Type of current period | FilingDateInstant | HY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |